Investors

News & Publications

News Releases

News Releases

November 6, 2019
Arvinas, Inc. Announces Pricing of Public Offering of Common Stock
NEW HAVEN, Conn. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the pricing of an underwritten public offering of 4,545,455 shares of its common stock at a price of $22.00
November 6, 2019
Arvinas, Inc. Announces Proposed Offering of Common Stock
NEW HAVEN, Conn. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it is commencing an underwritten public offering of $90.0 million of shares of its common stock.  In
August 7, 2019
Arvinas To Present at the Wedbush PacGrow Healthcare Conference
NEW HAVEN, Conn. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the company is scheduled to present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday,
Displaying 1 - 10 of 26